PROTON Technology

Framework for Collaboration in the Biomedical Sector

In the **biomedical field**, **PROTON EUROPE** operates under a **structured collaboration model**, aligned with the **scientific standards** and **technical responsibility** required by this sector.
We understand that many institutions request equipment under a **trial basis prior to investment decisions**. This is common practice when dealing with **early-stage technologies**.

PROTON is not an early-stage technology.
The technology has been **validated in Japan** and applied in **high-demand biomedical environments**.
In February 2026, the **Japanese Ministry of Health** approved for the first time worldwide the **commercialization** of two **regenerative medicine products** derived from **iPS cells**, intended for the treatment of **severe heart failure** and **Parkinson's disease**.
This **historic approval** marks the beginning of the **real clinical implementation** of iPS-based therapies in Japan.
One of these products, **AMCHEPRY (Sumitomo Pharma)**, uses **iPS-derived dopaminergic progenitor cells** for the treatment of **Parkinson's disease**, following demonstrated **safety and functional efficacy** in clinical studies, with **structural cryopreservation processes** developed within the **Japanese technological ecosystem** in which PROTON has been applied to **iPSC** and **dopaminergic neurospheres**.
The **cryopreservation of iPSC-derived dopaminergic neurospheres for clinical application** has been **scientifically documented in Japan**, demonstrating preservation of **viability**, **structural integrity**, and **post-thaw biological functionality** in advanced models.
This milestone confirms that Japan has entered the phase of **effective commercialization of advanced cellular therapies**, following more than **20 years of structured investment** in regenerative medicine research and development.

The development of PROTON for cellular applications originated in collaboration with the **National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN, Japan)** and the Japanese multinational **CHUBU**, and the biomedical configuration was specifically designed for **advanced structural cryopreservation**, including **iPSC** and **dopaminergic neurospheres**.

The model currently designated for biomedical applications is the **PF-15 NEO**, an optimized configuration for **structural cellular freezing**.
Therefore, we are not discussing a technology seeking **initial validation**, but an **already developed, tested, and optimized structural platform**, implemented in collaboration with **leading Japanese scientific institutions**.

Each **PROTON PF-15 NEO unit**:
- Is **manufactured on demand**
- Requires **specific configuration**
- Involves **technical calibration and specialized support**
- Represents a **structural ice crystallization control platform**, not a standard demonstration unit

For this reason, we do not establish **open loan or free demonstration models**.

Our collaborations in the biomedical sector are structured as:
Acquisition of the PF-15 NEO unit with a time-limited repurchase option.
This model allows:
- Ensuring **genuine institutional commitment**
- Establishing a **clearly defined scientific framework from the outset**
- Reducing **financial risk** for the institution

If, within the agreed evaluation period (typically up to **6 months**), the collaboration is not consolidated or defined objectives are not achieved, PROTON may exercise a **repurchase option**, deducting only a **monthly usage fee corresponding to the effective operational period**.

This approach maintains the balance between **accessibility and scientific rigor**, allowing us to focus our resources on projects with **solid technical structure and real institutional commitment**.
We sincerely appreciate the interest generated by the technology and remain open to evaluating each proposal within this **professional framework**.

2026年2月13日
RYOHO FREEZE SYSTEMS Co., Ltd.
KOHSEI YUGE
菱豊フリーズシステム株式会社
代表取締役

13 febrero 2026
PROTON EUROPE SL
MANUEL AYLLÓN
CEO PROTON EUROPE SL

PROTON EUROPE S.L.
ES-B67593004
Entença 196
08029 BARCELONA- SPAIN
+34 627925103
proton@innovafish.com
www.proton-europe.com